Skip to main content
. Author manuscript; available in PMC: 2024 Oct 2.
Published in final edited form as: N Engl J Med. 2023 Jun 4;389(7):589–601. doi: 10.1056/NEJMoa2304194

Figure 2. Progression-free Survival and Time to Next Intervention in the Full Analysis Set.

Figure 2.

Figure 2.

Panel A shows the Kaplan–Meier plot of the probability of imaging-based progression-free survival per blinded independent review among patients assigned to the vorasidenib group as compared with those assigned to the placebo group. Panel B shows the Kaplan–Meier plot of the probability of time to next anticancer treatment intervention among patients assigned to the vorasidenib group as compared with those assigned to the placebo group.

+Censored

CI confidence interval; HR hazard ratio.